These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9639252)

  • 21. Effects of radiochemical impurities on measurements of transfer constants for [14C]sucrose permeation of normal and injured blood-brain barrier of rats.
    Preston E; Foster DO; Mills PA
    Brain Res Bull; 1998; 45(1):111-6. PubMed ID: 9434211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynorphin A-(1-17) and dynorphin B are released from in vitro superfused rat hypothalami. Effects of depolarizing agents and ovariectomy.
    Spampinato S; Canossa M; Bachetti T; Campana G; Murari G; Ferri S
    Brain Res; 1992 May; 580(1-2):225-32. PubMed ID: 1354557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action.
    Faden AI; Jacobs TP
    Br J Pharmacol; 1984 Feb; 81(2):271-6. PubMed ID: 6142741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection against dynorphin-(1-8) hydrolysis in membrane preparations by the combination of amastatin, captopril and phosphoramidon.
    Hiranuma T; Kitamura K; Taniguchi T; Kanai M; Arai Y; Iwao K; Oka T
    J Pharmacol Exp Ther; 1998 Aug; 286(2):863-9. PubMed ID: 9694943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contrasting interactions of the locus coeruleus as compared to the ventral noradrenergic bundle with CNS and pituitary pools of vasopressin, dynorphin and related opioid peptides in the rat.
    Millan MJ; Millan MH; Członkowski A; Herz A
    Brain Res; 1984 Apr; 298(2):243-52. PubMed ID: 6144361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynorphin-(1-13): antinociceptive action and its effects on morphine analgesia and acute tolerance.
    Kishioka S; Morita N; Kitabata Y; Yamanishi T; Miyamoto Y; Ozaki M; Yamamoto H
    Jpn J Pharmacol; 1992 Nov; 60(3):197-207. PubMed ID: 1362787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers.
    Gambús PL; Schnider TW; Minto CF; Youngs EJ; Billard V; Brose WG; Hochhaus G; Shafer SL
    Clin Pharmacol Ther; 1998 Jul; 64(1):27-38. PubMed ID: 9695716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nitric oxide synthase inhibitors influence dynorphin A (1-17) immunoreactivity in the rat brain following hyperthermia.
    Sharma HS; Alm P
    Amino Acids; 2002; 23(1-3):247-59. PubMed ID: 12373545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dynorphin A (1-17), dynorphin A (1-13) and D-ala2-D-leu5-enkephalin on the excitability of pyramidal cells in CA1 and CA2 of the rat hippocampus in vitro.
    Vidal C; Maier R; Zieglgänsberger W
    Neuropeptides; 1984 Dec; 5(1-3):237-40. PubMed ID: 6152322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-performance liquid chromatographic system for the separation of dynorphin A (1-17) fragments and its application in enzymolysis studies with rat nerve terminal membranes.
    Seyfried CA; Tobler P
    J Chromatogr; 1990 Jul; 529(1):43-54. PubMed ID: 1976647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular effects of dynorphin A-(1-8), dynorphin A-(1-13) and dynorphin A-(1-17) microinjected into the preoptic medialis nucleus of the rat.
    Feuerstein G; Faden AI
    Neuropeptides; 1984 Dec; 5(1-3):295-8. PubMed ID: 6152328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of synaptic metabolites of dynorphin A (1-8) by electrospray ionization and tandem mass spectrometry.
    Prokai L; Zharikova AD
    Rapid Commun Mass Spectrom; 1998; 12(22):1796-800. PubMed ID: 9853388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynorphin A (1-8) analog, E-2078, crosses the blood-brain barrier in rhesus monkeys.
    Yu J; Butelman ER; Woods JH; Chait BT; Kreek MJ
    J Pharmacol Exp Ther; 1997 Aug; 282(2):633-8. PubMed ID: 9262324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of complex peptide degradation pathways via structured multicompartmental modeling approaches: the metabolism of dynorphin A1-13 and related fragments in human plasma.
    Müller S; Hutson A; Arya V; Hochhaus G
    J Pharm Sci; 1999 Sep; 88(9):938-44. PubMed ID: 10479358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions.
    Dehouck MP; Cecchelli R; Richard Green A; Renftel M; Lundquist S
    Brain Res; 2002 Nov; 955(1-2):229-35. PubMed ID: 12419541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynorphin A(6-12) analogs suppress thermal edema.
    Wei ET; Thomas HA; Gjerde EA; Reed RK; Burov SV; Korolkov VI; Glynskaya OV; Dorosh MY; Vlasov GP
    Peptides; 1998; 19(4):767-75. PubMed ID: 9622034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro biotransformation of dynorphin A (1-17) is similar in human and rhesus monkey blood as studied by matrix-assisted laser desorption/ionization mass spectrometry.
    Yu J; Butelman ER; Woods JH; Chait BT; Kreek MJ
    J Pharmacol Exp Ther; 1996 Nov; 279(2):507-14. PubMed ID: 8930152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain.
    Fang W; Zhang R; Sha L; Lv P; Shang E; Han D; Wei J; Geng X; Yang Q; Li Y
    J Neurochem; 2014 Mar; 128(5):662-71. PubMed ID: 24164378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions of dynorphin A-(1-13) and nociceptin with cardiac D2 binding sites: inhibition of ischemia-evoked release of noradrenaline from synaptosomal-mitochondrial fractions.
    Dumont M; Lemaire S
    J Mol Cell Cardiol; 2000 Aug; 32(8):1567-74. PubMed ID: 10900181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative studies of the neuro-excitatory behavioural effects of morphine-3-glucuronide and dynorphin A(2-17) following spinal and supraspinal routes of administration.
    Hemstapat K; Le L; Edwards SR; Smith MT
    Pharmacol Biochem Behav; 2009 Oct; 93(4):498-505. PubMed ID: 19580825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.